192 related articles for article (PubMed ID: 21621892)
1. [An introduction to competing risks analysis].
Pintilie M
Rev Esp Cardiol; 2011 Jul; 64(7):599-605. PubMed ID: 21621892
[TBL] [Abstract][Full Text] [Related]
2. Cumulative incidence in competing risks data and competing risks regression analysis.
Kim HT
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):559-65. PubMed ID: 17255278
[TBL] [Abstract][Full Text] [Related]
3. Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications.
Varadhan R; Weiss CO; Segal JB; Wu AW; Scharfstein D; Boyd C
Med Care; 2010 Jun; 48(6 Suppl):S96-105. PubMed ID: 20473207
[TBL] [Abstract][Full Text] [Related]
4. Competing time-to-event endpoints in cardiology trials: a simulation study to illustrate the importance of an adequate statistical analysis.
Rauch G; Kieser M; Ulrich S; Doherty P; Rauch B; Schneider S; Riemer T; Senges J
Eur J Prev Cardiol; 2014 Jan; 21(1):74-80. PubMed ID: 22964966
[TBL] [Abstract][Full Text] [Related]
5. On the importance of accounting for competing risks in pediatric cancer trials designed to delay or avoid radiotherapy: I. Basic concepts and first analyses.
Tai BC; Grundy RG; Machin D
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1493-9. PubMed ID: 19577860
[TBL] [Abstract][Full Text] [Related]
6. The analysis of case cohort design in the presence of competing risks with application to estimate the risk of delayed cardiac toxicity among Hodgkin lymphoma survivors.
Pintilie M; Bai Y; Yun L; Hodgson DC
Stat Med; 2010 Nov; 29(27):2802-10. PubMed ID: 20827727
[TBL] [Abstract][Full Text] [Related]
7. Dealing with competing risks: testing covariates and calculating sample size.
Pintilie M
Stat Med; 2002 Nov; 21(22):3317-24. PubMed ID: 12407674
[TBL] [Abstract][Full Text] [Related]
8. A competing-risks nomogram for sarcoma-specific death following local recurrence.
Kattan MW; Heller G; Brennan MF
Stat Med; 2003 Nov; 22(22):3515-25. PubMed ID: 14601016
[TBL] [Abstract][Full Text] [Related]
9. Competing risks and time-dependent covariates.
Cortese G; Andersen PK
Biom J; 2010 Feb; 52(1):138-58. PubMed ID: 20029852
[TBL] [Abstract][Full Text] [Related]
10. Overestimation of prostate cancer mortality and other-cause mortality by the Kaplan-Meier method.
Zhu X; Kranse R; Bul M; Bangma CH; Schröder FH; Roobol MJ
Can J Urol; 2013 Jun; 20(3):6756-60. PubMed ID: 23783043
[TBL] [Abstract][Full Text] [Related]
11. Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring.
Geskus RB
Biometrics; 2011 Mar; 67(1):39-49. PubMed ID: 20377575
[TBL] [Abstract][Full Text] [Related]
12. Competing events influence estimated survival probability: when is Kaplan-Meier analysis appropriate?
Biau DJ; Latouche A; Porcher R
Clin Orthop Relat Res; 2007 Sep; 462():229-33. PubMed ID: 17496556
[TBL] [Abstract][Full Text] [Related]
13. Prognostic models with competing risks: methods and application to coronary risk prediction.
Wolbers M; Koller MT; Witteman JC; Steyerberg EW
Epidemiology; 2009 Jul; 20(4):555-61. PubMed ID: 19367167
[TBL] [Abstract][Full Text] [Related]
14. Sample sizes for clinical trials with time-to-event endpoints and competing risks.
Schulgen G; Olschewski M; Krane V; Wanner C; Ruf G; Schumacher M
Contemp Clin Trials; 2005 Jun; 26(3):386-96. PubMed ID: 15911472
[TBL] [Abstract][Full Text] [Related]
15. Performing Survival Analyses in the Presence of Competing Risks: A Clinical Example in Older Breast Cancer Patients.
de Glas NA; Kiderlen M; Vandenbroucke JP; de Craen AJ; Portielje JE; van de Velde CJ; Liefers GJ; Bastiaannet E; Le Cessie S
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26614095
[TBL] [Abstract][Full Text] [Related]
16. Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches.
Tai BC; Machin D; White I; Gebski V;
Stat Med; 2001 Mar; 20(5):661-84. PubMed ID: 11241570
[TBL] [Abstract][Full Text] [Related]
17. Simulating competing risks data in survival analysis.
Beyersmann J; Latouche A; Buchholz A; Schumacher M
Stat Med; 2009 Mar; 28(6):956-71. PubMed ID: 19125387
[TBL] [Abstract][Full Text] [Related]
18. Quantifying the predictive accuracy of time-to-event models in the presence of competing risks.
Schoop R; Beyersmann J; Schumacher M; Binder H
Biom J; 2011 Feb; 53(1):88-112. PubMed ID: 21259311
[TBL] [Abstract][Full Text] [Related]
19. The analysis of competing events like cause-specific mortality--beware of the Kaplan-Meier method.
Verduijn M; Grootendorst DC; Dekker FW; Jager KJ; le Cessie S
Nephrol Dial Transplant; 2011 Jan; 26(1):56-61. PubMed ID: 21059831
[TBL] [Abstract][Full Text] [Related]
20. Model selection in competing risks regression.
Kuk D; Varadhan R
Stat Med; 2013 Aug; 32(18):3077-88. PubMed ID: 23436643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
